Spyre CFO Scott Burrows sells $716,771 in stock

au.investing.com

Spyre Therapeutics CFO Scott Burrows sold $716,771 worth of shares on August 3, 2026, near the stock's 52-week high. Sales followed exercising options at $14.50 per share, executed under a Rule 10b5-1 plan. He now owns 97,994 shares. The stock has returned 554% over the past year, though analysts flag valuation concerns. Recent positive phase 2 trial data for ulcerative colitis drug SPY002 led analysts to raise price targets, but other insider selling and a downgrade create a mixed outlook.


With a significance score of 0.9, this news ranks in the top 77% of today's 32633 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Spyre CFO Scott Burrows sells $716,771 in stock | News Minimalist